 |
0 Diseases |  |
3 Trials |
|
3 Trials |  |
52 News |  |
| 12» |
- ||| lacnotuzumab (MCS110) / Novartis
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: MCS110 With BRAF/MEK Inhibition in Patients With Melanoma (clinicaltrials.gov) - Jul 31, 2024
P1/2, N=6, Completed, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed | N=43 --> 6 | Trial completion date: Sep 2025 --> Sep 2023 | Trial primary completion date: Sep 2024 --> Sep 2023
- || lacnotuzumab (MCS110) / Novartis, spartalizumab (PDR001) / Novartis
P1/2 data, Journal, Combination therapy, Metastases: Phase Ib/II Study of Lacnotuzumab in Combination with Spartalizumab in Patients with Advanced Malignancies. (Pubmed Central) - May 9, 2024
P1/2
However, gating criteria for efficacy were not met for expansion beyond 80 patients in phase II and the sponsor did not continue development of the combination of spartalizumab and lacnotuzumab for oncology indications. The potential signal of activity in pancreatic cancer should be further explored.
- || Review, Journal: Updates on the Treatment of Tenosynovial Giant Cell Tumor. (Pubmed Central) - Jun 30, 2023
Pexidartinib is the first CSF-1 receptor inhibitor approved for the treatment of TGCT. Here, we discuss various available treatment strategies and ongoing investigations and trials targeting diffuse TGCT, which include nilotinib, lacnotuzumab, cabiralizumab, vimseltinib, and emactuzumab.
- || lacnotuzumab (MCS110) / Novartis
P1/2 data, Clinical Trial,Phase I, Clinical Trial,Phase II, Journal, IO biomarker: A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition. (Pubmed Central) - Jun 26, 2023
MCS110 in combination with dabrafenib and trametinib was reasonably well tolerated in a small melanoma population. One response was observed in this small sample of patients suggesting this combination might be worthy of further exploration.
- |||| Trial termination, IO biomarker: Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). (clinicaltrials.gov) - Feb 24, 2023
P1, N=64, Terminated, Sponsor: Novartis Pharmaceuticals
One response was observed in this small sample of patients suggesting this combination might be worthy of further exploration. Active, not recruiting --> Terminated; This was a sponsor decision and was not a consequence of any safety concern
- || Trial completion date, Trial primary completion date, IO biomarker: Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). (clinicaltrials.gov) - Nov 21, 2022
P1, N=64, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Terminated; This was a sponsor decision and was not a consequence of any safety concern Trial completion date: Oct 2022 --> Feb 2023 | Trial primary completion date: Oct 2022 --> Feb 2023
- || Trial completion date, Trial primary completion date, IO biomarker: Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). (clinicaltrials.gov) - Jul 19, 2022
P1, N=64, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Oct 2022 --> Feb 2023 | Trial primary completion date: Oct 2022 --> Feb 2023 Trial completion date: Jun 2022 --> Oct 2022 | Trial primary completion date: Jun 2022 --> Oct 2022
- || lacnotuzumab (MCS110) / Novartis
Clinical, P2 data, Journal: A Randomized Phase II Study of Anti-CSF-1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple Negative Breast Cancer. (Pubmed Central) - Apr 8, 2022
Despite successful target engagement and anticipated pharmacokinetic profile, lacnotuzumab+gem-carbo showed comparable antitumor activity to gem-carbo alone, with slightly poorer tolerability. However, the data presented in this manuscript would be informative for future studies testing agents targeting the CSF-1-CSF-1R pathway in TNBC.
- || Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, IO biomarker: Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). (clinicaltrials.gov) - Jan 27, 2022
P1, N=64, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
However, the data presented in this manuscript would be informative for future studies testing agents targeting the CSF-1-CSF-1R pathway in TNBC. Recruiting --> Active, not recruiting | N=220 --> 64 | Trial completion date: Jan 2022 --> Jun 2022 | Trial primary completion date: Jan 2022 --> Jun 2022
- | lacnotuzumab (MCS110) / Novartis
Trial primary completion date: MCS110 With BRAF/MEK Inhibition in Patients With Melanoma (clinicaltrials.gov) - Dec 10, 2021
P1/2, N=43, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting | N=220 --> 64 | Trial completion date: Jan 2022 --> Jun 2022 | Trial primary completion date: Jan 2022 --> Jun 2022 Trial primary completion date: Sep 2021 --> Sep 2024
- ||||| lacnotuzumab (MCS110) / Novartis, carboplatin / Generic mfg., gemcitabine / Generic mfg.
Clinical: Combination of anti CSF-1 #lacnotuzumab with #gemcitabine and #carboplatin in patients with advanced #TNBC shows antitumor activity comparable to #chemotherapy alone but slightly poorer tolerability. https://t.co/S3IDgtwqnQ @ava_kwong @ggste @FrancoisDuhoux (Twitter) - Oct 11, 2021
- lacnotuzumab (MCS110) / Novartis, Zelboraf (vemurafenib) / Roche
[VIRTUAL] M-CSF secreted factor as a therapeutic target in BRAFV600E acquired resistant melanoma () - Apr 18, 2021 - Abstract #EADOWCM2021EADO-WCM_684;
We have described for the first time an increase of M-CSF secretion in resistant BRAFV600E-mutant melanoma cells and its promotion to induce BRAFi-resistant phenotype. Antibodies against M-CSF may offer a new promising therapy to deal with resistant melanoma patients.
- lacnotuzumab (MCS110) / Novartis, spartalizumab (PDR001) / Novartis
[VIRTUAL] On-target peripheral and tumor immune microenvironment modulation in patients treated with lacnotuzumab (anti-CSF1, MCS110) + spartalizumab () - Mar 11, 2021 - Abstract #AACR2021AACR_821;
Flow cytometric, circulating total CSF1 in plasma and gene expression profiling results demonstrated that targeting CSF-1 with lacnotuzumab in the periphery and tumor microenvironment leads to decrease in monocytes and reduced expression of macrophage associated genes in patients with advanced cancers. Unfortunately, in the heavily pretreated patient populations studied in this trial, only a limited clinical efficacy was demonstrated.
- | lacnotuzumab (MCS110) / Novartis
Enrollment closed: MCS110 With BRAF/MEK Inhibition in Patients With Melanoma (clinicaltrials.gov) - Jan 14, 2021
P1/2, N=43, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Unfortunately, in the heavily pretreated patient populations studied in this trial, only a limited clinical efficacy was demonstrated. Recruiting --> Active, not recruiting
- || lacnotuzumab (MCS110) / Novartis
Trial completion, Trial completion date, Trial primary completion date, Metastases: Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC) (clinicaltrials.gov) - Aug 9, 2020
P2, N=50, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial completion date: Jul 2020 --> Mar 2020 | Trial primary completion date: Jul 2020 --> Mar 2020
- ||| lacnotuzumab (MCS110) / Novartis, spartalizumab (PDR001) / Novartis
Trial completion, Combination therapy, Metastases: Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies (clinicaltrials.gov) - Jul 9, 2020
P1/2, N=141, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial completion date: Jul 2020 --> Mar 2020 | Trial primary completion date: Jul 2020 --> Mar 2020 Active, not recruiting --> Completed
- | lacnotuzumab (MCS110) / Novartis
Trial completion date, Trial primary completion date, Metastases: Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC) (clinicaltrials.gov) - Apr 27, 2020
P2, N=50, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Trial completion date: Mar 2020 --> Jul 2020 | Trial primary completion date: Dec 2019 --> Jul 2020
- ||| lacnotuzumab (MCS110) / Novartis, spartalizumab (PDR001) / Novartis
Enrollment open, Combination therapy, Metastases: Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies (clinicaltrials.gov) - Jan 21, 2020
P1/2, N=175, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Mar 2020 --> Jul 2020 | Trial primary completion date: Dec 2019 --> Jul 2020 Active, not recruiting --> Recruiting
- || Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). (clinicaltrials.gov) - Jan 21, 2020
P1, N=220, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Recruiting Trial completion date: Oct 2020 --> Jan 2022 | Trial primary completion date: Oct 2020 --> Jan 2022
- | lacnotuzumab (MCS110) / Novartis
Trial completion date, Trial primary completion date, Metastases: Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC) (clinicaltrials.gov) - Oct 16, 2019
P2, N=50, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Oct 2020 --> Jan 2022 | Trial primary completion date: Oct 2020 --> Jan 2022 Trial completion date: Sep 2019 --> Mar 2020 | Trial primary completion date: Sep 2019 --> Dec 2019
- | lacnotuzumab (MCS110) / Novartis, spartalizumab (PDR001) / Novartis
Enrollment closed, Combination therapy, Metastases: Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies (clinicaltrials.gov) - Oct 16, 2019
P1/2, N=141, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Sep 2019 --> Mar 2020 | Trial primary completion date: Sep 2019 --> Dec 2019 Recruiting --> Active, not recruiting
- | lacnotuzumab (MCS110) / Novartis, spartalizumab (PDR001) / Novartis
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies (clinicaltrials.gov) - Jul 16, 2019
P1/2, N=175, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Trial completion date: May 2019 --> Nov 2019 | Trial primary completion date: May 2019 --> Nov 2019
- | lacnotuzumab (MCS110) / Novartis, spartalizumab (PDR001) / Novartis
Biomarker, Enrollment open, Combination therapy, PD(L)-1 Biomarker: Biomarker Study of PDR001 in Combination With MCS110 in Gastric Cancer (clinicaltrials.gov) - Apr 9, 2019
P2, N=30, Recruiting, Sponsor: Seoul National University Hospital
Trial completion date: May 2019 --> Nov 2019 | Trial primary completion date: May 2019 --> Nov 2019 Not yet recruiting --> Recruiting
- | lacnotuzumab (MCS110) / Novartis
Biomarker, Clinical, P1 data, Journal: CSF-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes. (Pubmed Central) - Mar 22, 2019
Preclinical investigations of the CK elevation and periorbital swelling observed after lacnotuzumab administration suggest that these are reversible, nonpathological events linked to inhibition of the CSF-1 pathway. These data support further evaluation of lacnotuzumab in clinical studies.
- || lacnotuzumab (MCS110) / Novartis
Trial completion: MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) (clinicaltrials.gov) - Mar 11, 2019
P2, N=36, Completed, Sponsor: Novartis Pharmaceuticals
These data support further evaluation of lacnotuzumab in clinical studies. Active, not recruiting --> Completed
- | lacnotuzumab (MCS110) / Novartis
Trial completion date, Trial primary completion date, Metastases: Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC) (clinicaltrials.gov) - Feb 18, 2019
P2, N=50, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Trial completion date: Dec 2018 --> Sep 2019 | Trial primary completion date: Dec 2018 --> Sep 2019
- ||| Enrollment open, PD(L)-1 Biomarker, IO biomarker: Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). (clinicaltrials.gov) - Feb 18, 2019
P1, N=220, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Dec 2018 --> Sep 2019 | Trial primary completion date: Dec 2018 --> Sep 2019 Not yet recruiting --> Recruiting
- | lacnotuzumab (MCS110) / Novartis
New P1/2 trial: MCS110 With BRAF/MEK Inhibition in Patients With Melanoma (clinicaltrials.gov) - Dec 25, 2018
P1/2, N=43, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
- | New P1 trial, PD(L)-1 Biomarker, IO biomarker: Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). (clinicaltrials.gov) - Nov 15, 2018
P1, N=220, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- | lacnotuzumab (MCS110) / Novartis, spartalizumab (PDR001) / Novartis
Biomarker, New P2 trial, Combination therapy, PD(L)-1 Biomarker: Biomarker Study of PDR001 in Combination With MCS110 in Gastric Cancer (clinicaltrials.gov) - Oct 2, 2018
P2, N=30, Not yet recruiting, Sponsor: Seoul National University Hospital
- | lacnotuzumab (MCS110) / Novartis
Enrollment change, Trial withdrawal: MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer (clinicaltrials.gov) - Aug 16, 2018
P1, N=0, Withdrawn, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting N=27 --> 0 | Not yet recruiting --> Withdrawn
- || lacnotuzumab (MCS110) / Novartis
Enrollment open: MCS110 With BRAF/MEK Inhibition in Patients With Melanoma (clinicaltrials.gov) - Aug 3, 2018
P1/2, N=43, Recruiting, Sponsor: Dana-Farber Cancer Institute
N=27 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting
- | lacnotuzumab (MCS110) / Novartis
Trial primary completion date, Metastases: Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC) (clinicaltrials.gov) - Jul 20, 2018
P2, N=50, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2018 --> Dec 2018
- | lacnotuzumab (MCS110) / Novartis
Trial completion date, Trial initiation date, Trial primary completion date: MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer (clinicaltrials.gov) - Jul 20, 2018
P1, N=27, Not yet recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Mar 2018 --> Dec 2018 Trial completion date: Nov 2020 --> Feb 2021 | Initiation date: Jun 2018 --> Sep 2018 | Trial primary completion date: Jul 2019 --> Oct 2019
- | lacnotuzumab (MCS110) / Novartis
Trial completion date: MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) (clinicaltrials.gov) - Jun 20, 2018
P2, N=36, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Nov 2020 --> Feb 2021 | Initiation date: Jun 2018 --> Sep 2018 | Trial primary completion date: Jul 2019 --> Oct 2019 Trial completion date: May 2021 --> Oct 2018
- lacnotuzumab (MCS110) / Novartis
Trial completion date, Trial initiation date, Trial primary completion date: MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer (clinicaltrials.gov) - Mar 8, 2018
P1, N=27, Not yet recruiting, Sponsor: Washington University School of Medicine
Trial completion date: May 2021 --> Oct 2018 Trial completion date: Jul 2020 --> Sep 2020 | Initiation date: Feb 2018 --> Apr 2018 | Trial primary completion date: Mar 2019 --> May 2019
- || lacnotuzumab (MCS110) / Novartis, spartalizumab (PDR001) / Novartis
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies (clinicaltrials.gov) - Feb 23, 2018
P1/2, N=175, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Jul 2020 --> Sep 2020 | Initiation date: Feb 2018 --> Apr 2018 | Trial primary completion date: Mar 2019 --> May 2019 Trial primary completion date: Jul 2018 --> May 2019 | Trial completion date: Jun 2019 --> May 2019
- | lacnotuzumab (MCS110) / Novartis
Enrollment closed, Trial primary completion date: MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) (clinicaltrials.gov) - Jan 4, 2018
P2, N=41, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jul 2018 --> May 2019 | Trial completion date: Jun 2019 --> May 2019 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2019 --> Feb 2018
- | lacnotuzumab (MCS110) / Novartis
Enrollment closed, Enrollment change, Metastases: Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC) (clinicaltrials.gov) - Dec 29, 2017
P2, N=50, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2019 --> Feb 2018 Recruiting --> Active, not recruiting | N=100 --> 50 | Recruiting --> Active, not recruiting | N=100 --> 50
- | lacnotuzumab (MCS110) / Novartis
New P1 trial: MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer (clinicaltrials.gov) - Sep 17, 2017
P1, N=27, Not yet recruiting, Sponsor: Washington University School of Medicine
- ||| lacnotuzumab (MCS110) / Novartis, spartalizumab (PDR001) / Novartis
Enrollment change, Combination therapy, Metastases: Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies (clinicaltrials.gov) - May 19, 2017
P1/2, N=196, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=100 --> 50 | Recruiting --> Active, not recruiting | N=100 --> 50 N=95 --> 196
- lacnotuzumab (MCS110) / Novartis
Trial primary completion date: MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) (clinicaltrials.gov) - May 8, 2017
P2, N=39, Recruiting, Sponsor: Novartis Pharmaceuticals
N=95 --> 196 Trial primary completion date: Dec 2018 --> Sep 2019
- || lacnotuzumab (MCS110) / Novartis
Trial primary completion date, Metastases: Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC) (clinicaltrials.gov) - Mar 20, 2017
P2, N=100, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2018 --> Sep 2019 Trial primary completion date: Mar 2019 --> Mar 2018
- || lacnotuzumab (MCS110) / Novartis, spartalizumab (PDR001) / Novartis
Trial primary completion date, Combination therapy, Metastases: Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies (clinicaltrials.gov) - Mar 1, 2017
P1/2, N=95, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Mar 2019 --> Mar 2018 Trial primary completion date: Jun 2019 --> Jul 2018
- || lacnotuzumab (MCS110) / Novartis, spartalizumab (PDR001) / Novartis
Trial primary completion date, Combination therapy, Metastases: Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies (clinicaltrials.gov) - Nov 23, 2016
P1/2, N=95, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jun 2019 --> Jul 2018 Trial primary completion date: Feb 2019 --> Jun 2019
- ||| lacnotuzumab (MCS110) / Novartis
Metastases: Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC) (clinicaltrials.gov) - Sep 12, 2016
P2, N=100, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Feb 2019 --> Jun 2019 N=78 --> 100 | Trial primary completion date: Jul 2018 --> Mar 2019
- |||| lacnotuzumab (MCS110) / Novartis, spartalizumab (PDR001) / Novartis
Enrollment open, Combination therapy, Metastases: Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies (clinicaltrials.gov) - Jul 20, 2016
P1/2, N=95, Recruiting, Sponsor: Novartis Pharmaceuticals
N=78 --> 100 | Trial primary completion date: Jul 2018 --> Mar 2019 Not yet recruiting --> Recruiting
- | lacnotuzumab (MCS110) / Novartis
Enrollment change, Trial primary completion date: MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) (clinicaltrials.gov) - Jul 11, 2016
P2, N=37, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting N=18 --> 37 | Trial primary completion date: Nov 2017 --> Dec 2018
- ||||| lacnotuzumab (MCS110) / Novartis, spartalizumab (PDR001) / Novartis
New P1/2 trial, Combination therapy, Metastases: Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies (clinicaltrials.gov) - Jun 21, 2016
P1/2, N=95, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- lacnotuzumab (MCS110) / Novartis
Trial primary completion date: MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) (clinicaltrials.gov) - Jan 17, 2016
P2, N=18, Recruiting, Sponsor: Novartis Pharmaceuticals
N=18 --> 37 | Trial primary completion date: Nov 2017 --> Dec 2018 Trial primary completion date: Mar 2017 --> Nov 2017